Epstein-Barr virus latent membrane protein 1 peptide–HLA complex (EBV LMP1-HLA complex)

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) peptide–HLA complex is a tumor-specific target presented on the surface of EBV-infected malignant cells [1]. LMP1 is a primary viral oncogene that acts as a constitutively active mimic of the CD40 receptor, triggering signaling pathways such as NF-κB and MAPK to promote cell survival, proliferation, and immune evasion [2]. Because LMP1 is a multi-pass transmembrane protein with minimal extracellular exposure, it is challenging to target with standard monoclonal antibodies. However, its intracellular degradation produces specific peptides, such as the immunodominant YLLEMLWRL epitope, which are loaded onto HLA class I or II molecules and transported to the cell surface [3]. These peptide-HLA complexes serve as unique signatures for EBV-associated malignancies, including nasopharyngeal carcinoma and various lymphomas. Therapeutic strategies currently under development, such as TCR-like antibodies and TCR-engineered T cells, are designed to recognize these complexes with high specificity, enabling the selective destruction of cancer cells while sparing healthy, non-infected tissues [4].

Other names

LMP1-MHC complexEBV LMP1-derived peptide–MHC class I complexLMP1-HLA-A*02:01 complexYLLEMLWRL-HLA-A2 complexLMP1-pMHC

Targeted cell lysis via T-cell mediated cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), or redirected T-cell engagement following specific binding to the peptide-HLA complex on the tumor cell surface.